Pay in 4 interest-free payments of $7.44 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism
Overweight adults with T2D who receive either semaglutide or standard glucose-lowering therapy (sitagliptin, empagliflozin, glipizide) Overweight adults without T2D who receive either semaglutide or usual anti-obesity drugs (Contrave, phentermine, Qsymia) The objective was to evaluate the risk of skeletal outcomes such as osteoporosis, osteoarthritis (hip and knee), gout, and other bone density disorders
PlexusDx sources both medications exclusively from licensed 503A compounding pharmacies meeting strict regulatory standards for purity and potency
Neither is strictly better, it depends on the individual
If TRIUMPH-1 confirms 25-30% weight loss in the general obesity population (not just osteoarthritis patients), Lilly has a strong argument for premium pricing
US$ 24.33
US$ 26.03
US$ 23.86
US$ 21.73
US$ 27.29
US$ 25.34
